QuidelOrtho Corp. (NASDAQ:QDEL) on Wednesday released its preliminary first-quarter 2026 revenue.
Weak Flu Season, China Snags Weigh On Q1 Sales
The diagnostic healthcare products maker reported preliminary unaudited revenue in the range of $615 million to $620 million for the first quarter, compared to the consensus of $680.59 million.
The results reflect a weaker respiratory season, with U.S. Influenza-like Illness visits down about 30% compared to the prior-year period, along with slower China distributor sales and delays in certain EMEA orders, the company said.
The San Diego, California-based company also expects free cash flow to be negative in the first half of 2026, with first-quarter free cash flow projected in the range of $(65) million to $(70) million.
Still, the full-year 2026 free cash flow is expected to be positive.
Analyst Flags Execution Risks Despite Management Confidence
William Blair said management still believes hitting the low end of its guidance is achievable following the update, but analyst Andrew Brackmann expects investors to remain skeptical.
Reaching the low end would depend on several favorable assumptions: a typical fourth-quarter respiratory season, no meaningful reimbursement changes in China—where visibility remains limited—and a normalization in the Middle East, which accounts for 3%–4% of sales and has yet to show improvement despite the ceasefire.
China Uncertainty And Segment Weakness Cloud Outlook
William Blair expects estimates to fall below the guidance range, particularly given ongoing uncertainty in China. Any disruption in that high-margin segment could have an outsized impact on earnings.
While factors outside management’s control largely drove the first-quarter miss, the analyst believes investors will focus on broader risks.
The core business, representing about 70% of revenue, remains solid, but weakness in the remaining 30% is weighing on overall financial performance. Elevated debt levels and limited near-term free cash flow compound this.
The stock’s decline reflects continued concern around the China business, where management has limited control.
Potential reimbursement changes add another layer of uncertainty, with unclear timing and financial impact.
QDEL Price Action: QuidelOrtho shares were down 32.13% at $11.87 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Recent Comments